Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Interactions of NK cell receptor KIR3DL1*004 with chaperones and conformation-specific antibody reveal a functional folded state as well as predominant intracellular retention.

Taner SB, Pando MJ, Roberts A, Schellekens J, Marsh SG, Malmberg KJ, Parham P, Brodsky FM.

J Immunol. 2011 Jan 1;186(1):62-72. doi: 10.4049/jimmunol.0903657. Epub 2010 Nov 29.

2.

HIV infection abrogates the functional advantage of natural killer cells educated through KIR3DL1/HLA-Bw4 interactions to mediate anti-HIV antibody-dependent cellular cytotoxicity.

Parsons MS, Wren L, Isitman G, Navis M, Stratov I, Bernard NF, Kent SJ.

J Virol. 2012 Apr;86(8):4488-95. doi: 10.1128/JVI.06112-11. Epub 2012 Feb 15.

3.

Polymorphic sites away from the Bw4 epitope that affect interaction of Bw4+ HLA-B with KIR3DL1.

Sanjanwala B, Draghi M, Norman PJ, Guethlein LA, Parham P.

J Immunol. 2008 Nov 1;181(9):6293-300.

4.

HLA alleles determine differences in human natural killer cell responsiveness and potency.

Kim S, Sunwoo JB, Yang L, Choi T, Song YJ, French AR, Vlahiotis A, Piccirillo JF, Cella M, Colonna M, Mohanakumar T, Hsu KC, Dupont B, Yokoyama WM.

Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3053-8. doi: 10.1073/pnas.0712229105. Epub 2008 Feb 19.

5.

Human immunodeficiency virus type 1 infection is associated with increased NK cell polyfunctionality and higher levels of KIR3DL1+ NK cells in ugandans carrying the HLA-B Bw4 motif.

Eller MA, Koehler RN, Kijak GH, Eller LA, Guwatudde D, Marovich MA, Michael NL, de Souza MS, Wabwire-Mangen F, Robb ML, Currier JR, Sandberg JK.

J Virol. 2011 May;85(10):4802-11. doi: 10.1128/JVI.00111-11. Epub 2011 Mar 16.

6.

Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1*h/*y and HLA-B*57.

Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Côté P, Boulassel MR, Baril JG, Kovacs C, Migueles SA, Connors M, Suscovich TJ, Brander C, Tremblay CL, Bernard N; Canadian Cohort of HIV Infected Slow Progressors.

J Virol. 2011 Jun;85(12):5949-60. doi: 10.1128/JVI.02652-10. Epub 2011 Apr 6.

7.

Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells.

Parsons MS, Zipperlen K, Gallant M, Grant M.

J Leukoc Biol. 2010 Nov;88(5):905-12. doi: 10.1189/jlb.1009687. Epub 2010 Jul 27.

PMID:
20664023
8.

Common HIV-1 peptide variants mediate differential binding of KIR3DL1 to HLA-Bw4 molecules.

Fadda L, O'Connor GM, Kumar S, Piechocka-Trocha A, Gardiner CM, Carrington M, McVicar DW, Altfeld M.

J Virol. 2011 Jun;85(12):5970-4. doi: 10.1128/JVI.00412-11. Epub 2011 Apr 6.

9.

KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding.

Mulrooney TJ, Zhang AC, Goldgur Y, Boudreau JE, Hsu KC.

J Immunol. 2015 Aug 1;195(3):1242-50. doi: 10.4049/jimmunol.1500243. Epub 2015 Jun 24.

10.

Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells.

O'Connor GM, Guinan KJ, Cunningham RT, Middleton D, Parham P, Gardiner CM.

J Immunol. 2007 Jan 1;178(1):235-41.

11.

The interaction of KIR3DL1*001 with HLA class I molecules is dependent upon molecular microarchitecture within the Bw4 epitope.

Saunders PM, Vivian JP, Baschuk N, Beddoe T, Widjaja J, O'Connor GM, Hitchen C, Pymm P, Andrews DM, Gras S, McVicar DW, Rossjohn J, Brooks AG.

J Immunol. 2015 Jan 15;194(2):781-789. doi: 10.4049/jimmunol.1402542. Epub 2014 Dec 5.

12.

Mutational and structural analysis of KIR3DL1 reveals a lineage-defining allotypic dimorphism that impacts both HLA and peptide sensitivity.

O'Connor GM, Vivian JP, Widjaja JM, Bridgeman JS, Gostick E, Lafont BA, Anderson SK, Price DA, Brooks AG, Rossjohn J, McVicar DW.

J Immunol. 2014 Mar 15;192(6):2875-84. doi: 10.4049/jimmunol.1303142. Epub 2014 Feb 21.

13.

Human leukocyte antigens A23, A24, and A32 but not A25 are ligands for KIR3DL1.

Stern M, Ruggeri L, Capanni M, Mancusi A, Velardi A.

Blood. 2008 Aug 1;112(3):708-10. doi: 10.1182/blood-2008-02-137521. Epub 2008 May 23.

14.

Cutting Edge: Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B.

Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, Easterbrook P, McVicar DW, Maenaka K, Parham P, Carrington M, Dong T, Rowland-Jones S.

J Immunol. 2007 Jan 1;178(1):33-7.

15.

Hematopoietic stem cell transplantation: Improving alloreactive Bw4 donor selection by genotyping codon 86 of KIR3DL1/S1.

Alicata C, Pende D, Meazza R, Canevali P, Loiacono F, Bertaina A, Locatelli F, Nemat-Gorgani N, Guethlein LA, Parham P, Moretta L, Moretta A, Bottino C, Norman PJ, Falco M.

Eur J Immunol. 2016 Jun;46(6):1511-7. doi: 10.1002/eji.201546236.

16.

KIR3DL1 and HLA-B Density and Binding Calibrate NK Education and Response to HIV.

Boudreau JE, Mulrooney TJ, Le Luduec JB, Barker E, Hsu KC.

J Immunol. 2016 Apr 15;196(8):3398-410. doi: 10.4049/jimmunol.1502469. Epub 2016 Mar 9.

17.

HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells.

Boulet S, Song R, Kamya P, Bruneau J, Shoukry NH, Tsoukas CM, Bernard NF.

J Immunol. 2010 Feb 15;184(4):2057-64. doi: 10.4049/jimmunol.0902621. Epub 2010 Jan 8.

18.

KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma.

Forlenza CJ, Boudreau JE, Zheng J, Le Luduec JB, Chamberlain E, Heller G, Cheung NK, Hsu KC.

J Clin Oncol. 2016 Jul 20;34(21):2443-51. doi: 10.1200/JCO.2015.64.9558. Epub 2016 Apr 11.

19.

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1.

O'Connor GM, Vivian JP, Gostick E, Pymm P, Lafont BA, Price DA, Rossjohn J, Brooks AG, McVicar DW.

J Virol. 2015 May;89(10):5213-21. doi: 10.1128/JVI.03586-14. Epub 2015 Mar 4. Erratum in: J Virol. 2015 Jul;89(14):7442.

20.

Mind the gap: lack of association between KIR3DL1*004/HLA‐Bw4-induced natural killer cell function and protection from HIV infection.

Parsons MS, Boulet S, Song R, Bruneau J, Shoukry NH, Routy JP, Tsoukas CM, Bernard NF.

J Infect Dis. 2010 Nov 1;202 Suppl 3:S356-60. doi: 10.1086/655966.

PMID:
20887224

Supplemental Content

Support Center